BCR and mantle cell lymphoma: In a pre‐clinical setting, it has been previously demonstrated that targeting FAK and/or PYK2 could bring some benefits in some haematological cancers such as Multiple Myeloma,14 Myelodysplastic Syndromes,15 Acute Myeloid Leukaemia,16 BCR/ABL‐transformed model of Chronic Myeloid Leukaemia17 and in Mantle Cell Lymphoma (MCL).